Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Assets (2020 - 2025)

Historic Assets for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $43.9 million.

  • Insight Molecular Diagnostics' Assets fell 3742.59% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 3742.59%. This contributed to the annual value of $35.1 million for FY2024, which is 5315.79% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Assets of $43.9 million as of Q3 2025, which was down 3742.59% from $50.5 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Assets' 5-year high stood at $177.4 million during Q2 2021, with a 5-year trough of $35.1 million in Q4 2024.
  • For the 5-year period, Insight Molecular Diagnostics' Assets averaged around $99.3 million, with its median value being $81.6 million (2023).
  • In the last 5 years, Insight Molecular Diagnostics' Assets skyrocketed by 19136.84% in 2021 and then tumbled by 5315.79% in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Assets stood at $159.6 million in 2021, then plummeted by 37.27% to $100.1 million in 2022, then dropped by 25.18% to $74.9 million in 2023, then plummeted by 53.16% to $35.1 million in 2024, then rose by 25.24% to $43.9 million in 2025.
  • Its Assets stands at $43.9 million for Q3 2025, versus $50.5 million for Q2 2025 and $60.4 million for Q1 2025.